Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, acting as part of a comprehensive diabetes management plan.

GNH USA supplies Jazeta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Sitagliptin Hydrochloride is used to manage hyperglycaemia in the type 2 diabetes mellitus pathway. - Type 2 diabetes mellitus (monotherapy): lowers HbA1c when added to diet and exercise. - Type 2 diabetes mellitus (combination therapy): used with metformin, sulfonylureas or insulin to enhance glycaemic control. - Type 2 diabetes mellitus with renal impairment (dose‑adjusted): provides glycaemic control when dosing is adjusted for renal function.

Adverse reactions may occur with sitagliptin therapy.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract inflammation. - Headache: transient mild to moderate pain. - Upper respiratory infection: symptoms of cough and congestion. - Gastrointestinal upset: nausea, abdominal discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: angioedema, urticaria, or anaphylaxis. - Joint pain: unexplained arthralgia. - Bullous pemphigoid: rare skin blistering disorder. - Hepatic injury: elevated liver enzymes or hepatitis.

Before initiating sitagliptin, consider the following safety measures. - Renal function assessment: adjust dose in patients with impaired renal function. - Monitor for pancreatitis: discontinue if severe abdominal pain develops. - Assess for hypersensitivity: stop therapy if rash, angioedema, or other allergic signs appear. - Use with caution in the elderly: increased susceptibility to adverse events. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Concomitant insulin secretagogues: increased risk of hypoglycaemia. - Sulfonylureas: may potentiate hypoglycaemic episodes. - Duplicate DPP‑4 inhibition: avoid using another DPP‑4 inhibitor concurrently.

Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function and electrolytes. - ACE inhibitors: watch for additive hypotensive effects. - Rifampin: may reduce sitagliptin plasma concentrations, requiring efficacy assessment.